Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
4(24%)
Results Posted
0%(0 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
1
6%
Ph not_applicable
3
18%
Ph phase_2
4
24%
Ph early_phase_1
1
6%
Ph phase_3
2
12%
Ph phase_4
5
29%

Phase Distribution

2

Early Stage

4

Mid Stage

7

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
1(6.3%)
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
4(25.0%)
Phase 3Large-scale testing
2(12.5%)
Phase 4Post-market surveillance
5(31.3%)
N/ANon-phased studies
3(18.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

4

trials recruiting

Total Trials

17

all time

Status Distribution
Active(4)
Completed(9)
Terminated(2)
Other(2)

Detailed Status

Completed9
Recruiting4
unknown1
Terminated1
Withdrawn1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
4
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (6.3%)
Phase 11 (6.3%)
Phase 24 (25.0%)
Phase 32 (12.5%)
Phase 45 (31.3%)
N/A3 (18.8%)

Trials by Status

unknown16%
completed953%
terminated16%
recruiting424%
withdrawn16%
suspended16%

Recent Activity

4 active trials
Showing 5 of 17
recruitingphase_2

Methimazole in Patients With Progressive Glioblastoma

NCT05607407
recruitingphase_2

Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

NCT07369063
suspendedphase_2

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

NCT06240455
recruitingphase_4

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

NCT05461820
recruitingphase_3

A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy

NCT04776993
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT05607407Phase 2

Methimazole in Patients With Progressive Glioblastoma

Recruiting
NCT07369063Phase 2

Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

Recruiting
NCT06240455Phase 2

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

Suspended
NCT05461820Phase 4

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

Recruiting
NCT04776993Phase 3

A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy

Recruiting
NCT05017610Early Phase 1

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Withdrawn
NCT05118542Phase 3

Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis

Completed
NCT02727738Not Applicable

Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole

Completed
NCT01458600Phase 4

Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)

Completed
NCT02376088

Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease

Completed
NCT00150124Phase 4

Block-replacement Therapy During Radioiodine Therapy

Completed
NCT01893450Not Applicable

Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment

Terminated
NCT01849861Phase 4

Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone

Unknown
NCT01560299Not Applicable

Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients

Completed
NCT00001421Phase 2

Methimazole to Treat Polymyositis and Dermatomyositis

Completed
NCT00150111Phase 1

Rituximab in the Treatment of Graves' Disease

Completed
NCT00150137Phase 4

Antithyroid Drugs During Radioiodine Therapy

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17